Incyte Corporation (INCY) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive a...
Analysis Summary
Incyte Corporation reported revenue of $5.14B in the most recent fiscal year, growing at a 5-year CAGR of 14.0%.
Trailing-twelve-month margins: gross margin 92.6%, operating margin 31.6%, net margin 27.7%.
At the current price of $121.47, INCY trades at a P/E of 15.34 and an ROE of 24.90%. Market capitalisation stands at $24.6B, placing it among large-cap names.
Balance sheet quality for INCY: current ratio of 3.3, net cash position of $3.51B. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Cash flow quality is strong: free cash flow of $1.35B represents 105% conversion of reported net income. High conversion (above 90%) suggests earnings translate cleanly into cash; lower conversion may indicate working capital tightness or accounting timing differences.
Price
| Price | $121.47 |
| Market Cap | $24.6B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 15.34 |
| Price / Book | 3.94 |
| EV / EBITDA | 9.23 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 24.90% |
| Return on Invested Capital | 20.58% |
| Return on Assets | 18.49% |
| Gross Margin | 92.62% |
| Operating Margin | 31.57% |
| Net Margin | 27.71% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 4.66 |
| Piotroski F-Score | 8 |
| Altman Z-Score | 8.44 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| INCY | Incyte Corporation | $24.6B | 15.34 | 3.94 | 24.9% |
| BIIB | Biogen Inc. | $31.9B | 37.86 | 1.69 | 4.5% |
| UTHR | United Therapeutics Corporation | $21.2B | 16.49 | 3.32 | |
| RPRX | Royalty Pharma plc | $26.0B | 24.39 | 3.83 | |
| ILMN | Illumina, Inc. | $34.6B | 45.56 | 13.12 | 31.1% |
| GMAB | Genmab A/S | $21.1B | 26.82 | 3.53 | 16.5% |
| DGX | Quest Diagnostics Incorporated | $26.2B | 25.90 | 3.62 | |
| WAT | Waters Corporation | $29.9B | 103.75 | 2.70 | 1.9% |
Price Performance
| 1 month | +1.04% |
| 3 months | +27.01% |
| Year-to-date | +26.30% |
| 1 year | +47.11% |
| 3 years | +109.63% |
| 5 years | +64.17% |
52-Week Range
| 52-week High | $132.60 |
| 52-week Low | $81.09 |
| Avg Volume (90d) | 1.7M |
Related companies: BIIB · DGX · GMAB · ILMN · RPRX · THC · UTHR
Explore sector: Healthcare · Biotechnology
More sections of INCY: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks